Allergan/ISTA Vitrase "approvable" for vitreous hemorrhage treatment (ovine hyaluronidase), FDA letter says. "FDA requested additional analysis of the existing data and an additional confirmatory clinical study based upon that analysis," ISTA said. FDA's Dermatologic & Ophthalmic Drugs Advisory Committee determined in March that existing data did not demonstrate efficacy, but said ISTA could analyze subgroups and effects on vision for further evidence of efficacy (1"The Pink Sheet" March 24, p. 33). "FDA also cited issues related to the drug substance and drug specifications," company said. FDA did not note any deficiencies in safety data, ISTA added...
You may also be interested in...
A subgroup analysis of Allergan/ISTA's Vitrase data could provide additional evidence for efficacy of the ophthalmic drug for treatment of vitreous hemorrhage, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee said March 17
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.